Home Applications 213312 Application 213312
Type NDA
Sponsor AADI BIOSCIENCE INC Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 FYARRO SIROLIMUS ALBUMIN-BOUND NANOPARTICLES POWDER;INTRAVENOUS 100MG/VIAL Yes No
Source provenance: Browse the complete Orange Book source catalog · source snapshot 42 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N213312-001 FYARRO SIROLIMUS 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22
Orange Book patents# Current patent rows page 1 of 1 · 9 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N213312-001 8911786 2029-02-14 U-3259 Drug product 2021-12-17 N213312-001 10206887 2030-04-15 Drug product 2021-12-17 N213312-001 10705070 2036-03-05 Drug product 2021-12-17 N213312-001 12061183 2036-03-05 Drug product 2024-08-13 N213312-001 10973806 2036-06-29 U-3258 2021-12-17 N213312-001 12133844 2036-06-29 U-4040 2024-12-04 N213312-001 12133844 2036-06-29 U-4041 2024-12-04 N213312-001 12133844 2036-06-29 U-4042 2024-12-04 N213312-001 11497737 2040-10-28 Drug product 2022-11-23
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 1 matching rows.
Application-product, Exclusivity code, Expiration table Application-product Exclusivity code Expiration N213312-001 ODE-386 2028-11-22
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-08-18 06:07:40 2026-07 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 301d65b070ca…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 1e350fbaab3a…2024-05-31 18:47 UTC 2024-05 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 8072bd15b7f6…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 5c6f7cd8ea54…2022-04-08 23:34 UTC 2022-04 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 5d02ea3f76ae…2022-04-04 05:41 UTC 2022-04 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 4b0b4de00fa7…2022-03-09 01:35 UTC 2022-03 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 bb7c543d1eb4…2021-12-28 21:50 UTC 2021-12 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 782e0a99824c…2024-03-16 18:09 UTC · 4 captures of this ZIP 2024-03 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 6a51e52b5d6a…2024-02-18 07:12 UTC 2024-02 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 1c564ffb4f44…2023-12-20 04:57 UTC 2023-12 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 ea1830bbd6c7…2023-11-28 05:40 UTC · 2 captures of this ZIP 2023-11 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 a72a2bbeb626…2023-10-25 00:34 UTC · 2 captures of this ZIP 2023-10 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 9b2671bbb829…2023-07-15 15:27 UTC · 2 captures of this ZIP 2023-07 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 a67488948f0b…2023-06-13 01:57 UTC · 3 captures of this ZIP 2023-06 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 3f0d92c62455…2023-05-13 08:27 UTC 2023-05 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 053a50430f4f…2023-01-26 05:58 UTC 2023-01 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 3bdfa0b2c4d7…2022-11-12 20:34 UTC · 5 captures of this ZIP 2022-11 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 3a93d1ddd44b…2022-10-28 04:53 UTC 2022-10 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 f41ea6bd6efb…2022-09-29 23:25 UTC 2022-09 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 e64feba35796…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 cb3db0bc1861…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N213312-001 FYARRO 100MG/VIAL POWDER / INTRAVENOUS RLD, RS 2021-11-22 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 5 · 196 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-08-18 06:07:40 2026-07 N213312-001 8911786 2029-02-14 U-3259 Drug product 2021-12-17 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213312-001 10206887 2030-04-15 Drug product 2021-12-17 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213312-001 10705070 2036-03-05 Drug product 2021-12-17 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213312-001 12061183 2036-03-05 Drug product 2024-08-13 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213312-001 10973806 2036-06-29 U-3258 2021-12-17 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213312-001 12133844 2036-06-29 U-4040 2024-12-04 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213312-001 12133844 2036-06-29 U-4041 2024-12-04 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213312-001 12133844 2036-06-29 U-4042 2024-12-04 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213312-001 11497737 2040-10-28 Drug product 2022-11-23 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N213312-001 8911786 2029-02-14 U-3259 Drug product 2021-12-17 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213312-001 10206887 2030-04-15 Drug product 2021-12-17 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213312-001 10705070 2036-03-05 Drug product 2021-12-17 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213312-001 12061183 2036-03-05 Drug product 2024-08-13 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213312-001 10973806 2036-06-29 U-3258 2021-12-17 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213312-001 12133844 2036-06-29 U-4040 2024-12-04 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213312-001 12133844 2036-06-29 U-4041 2024-12-04 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213312-001 12133844 2036-06-29 U-4042 2024-12-04 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213312-001 11497737 2040-10-28 Drug product 2022-11-23 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213312-001 8911786 2029-02-14 U-3259 Drug product 2021-12-17 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213312-001 10206887 2030-04-15 Drug product 2021-12-17 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213312-001 10705070 2036-03-05 Drug product 2021-12-17 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213312-001 12061183 2036-03-05 Drug product 2024-08-13 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213312-001 10973806 2036-06-29 U-3258 2021-12-17 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213312-001 12133844 2036-06-29 U-4040 2024-12-04 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213312-001 12133844 2036-06-29 U-4041 2024-12-04 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213312-001 12133844 2036-06-29 U-4042 2024-12-04 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213312-001 11497737 2040-10-28 Drug product 2022-11-23 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N213312-001 8911786 2029-02-14 U-3259 Drug product 2021-12-17 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N213312-001 10206887 2030-04-15 Drug product 2021-12-17 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N213312-001 10705070 2036-03-05 Drug product 2021-12-17 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N213312-001 12061183 2036-03-05 Drug product 2024-08-13 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N213312-001 10973806 2036-06-29 U-3258 2021-12-17 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N213312-001 12133844 2036-06-29 U-4040 2024-12-04 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N213312-001 12133844 2036-06-29 U-4041 2024-12-04 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N213312-001 12133844 2036-06-29 U-4042 2024-12-04 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N213312-001 11497737 2040-10-28 Drug product 2022-11-23 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N213312-001 8911786 2029-02-14 U-3259 Drug product 2021-12-17 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N213312-001 10206887 2030-04-15 Drug product 2021-12-17 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N213312-001 10705070 2036-03-05 Drug product 2021-12-17 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N213312-001 12061183 2036-03-05 Drug product 2024-08-13 fd3edfee7708…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 2 · 50 observed states.
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 2 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 80803-153 FYARRO Sirolimus Aadi Bioscience NDA Current 80803-153 FYARRO Sirolimus Aadi Bioscience NDA Current
Documents# Document, Submission type, Date table Document Submission type Date 71970 ORIG 2022-08-30 69408 ORIG 2021-11-24 69383 ORIG 2021-11-23